免疫检查点基因在肿瘤中的泛素化降解机制
Ubiquitination and Degradation Mechanisms of Immune Checkpoint Genes in Tumors
DOI: 10.12677/acm.2026.161264, PDF,   
作者: 窦家琪, 金 泽:空军军医大学基础医学院学员队,陕西 西安;赵晋波*:空军军医大学唐都医院胸腔外科,陕西 西安
关键词: 免疫检查点泛素化蛋白降解肿瘤免疫E3泛素连接酶Immune Checkpoint Ubiquitination Protein Degradation Tumor Immunity E3 Ligase
摘要: 免疫检查点蛋白作为重要的免疫调节分子,其表达水平直接影响肿瘤免疫治疗效果。研究发现泛素化降解途径在调控免疫检查点基因表达中发挥关键作用。通过系统分析PD-1与PD-L1以及CTLA-4等主要免疫检查点分子的泛素化降解机制,阐明E3泛素连接酶与去泛素化酶等关键分子在该过程中的调控作用,揭示泛素化修饰与免疫逃逸之间的关系。深入理解免疫检查点基因的泛素化降解调控网络,为开发新型肿瘤免疫治疗策略提供理论基础。
Abstract: As important immune regulatory molecules, the expression level of immune checkpoint proteins directly affects the efficacy of tumor immunotherapy. Research has found that the ubiquitination degradation pathway plays a key role in regulating immune checkpoint gene expression. By systematically analyzing the ubiquitination degradation mechanisms of major immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4, the regulatory roles of key molecules such as E3 ubiquitin ligase and deubiquitinase in this process are elucidated, revealing the relationship between ubiquitination modification and immune escape. A deep understanding of the ubiquitination degradation regulatory network of immune checkpoint genes provides a theoretical basis for developing novel tumor immunotherapy strategies.
文章引用:窦家琪, 金泽, 赵晋波. 免疫检查点基因在肿瘤中的泛素化降解机制[J]. 临床医学进展, 2026, 16(1): 2084-2091. https://doi.org/10.12677/acm.2026.161264

参考文献

[1] Meng, X., Liu, X., Guo, X., Jiang, S., Chen, T., Hu, Z., et al. (2018) FBXO38 Mediates PD-1 Ubiquitination and Regulates Anti-Tumour Immunity of T Cells. Nature, 564, 130-135. [Google Scholar] [CrossRef] [PubMed]
[2] Wu, Z., Cao, Z., Yao, H., Yan, X., Xu, W., Zhang, M., et al. (2023) Coupled Deglycosylation-Ubiquitination Cascade in Regulating PD-1 Degradation by MDM2. Cell Reports, 42, Article ID: 112693. [Google Scholar] [CrossRef] [PubMed]
[3] Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N.T., et al. (2017) Cyclin D-CDK4 Kinase Destabilizes PD-L1 via Cullin 3-SPOP to Control Cancer Immune Surveillance. Nature, 553, 91-95. [Google Scholar] [CrossRef] [PubMed]
[4] Tey, P.Y., Dufner, A., Knobeloch, K., Pruneda, J.N., Clague, M.J. and Urbé, S. (2024) Rapid Turnover of CTLA4 Is Associated with a Complex Architecture of Reversible Ubiquitylation. Journal of Cell Biology, 224, e202312141. [Google Scholar] [CrossRef] [PubMed]
[5] Jie, X., Guo, H. and Zhou, G. (2023) The E3 Ubiquitin Ligase TRAF6 Controls CTLA-4 Turnover and Promotes T-Cell-Mediated Antitumor Immunity. Cellular & Molecular Immunology, 21, 97-99. [Google Scholar] [CrossRef] [PubMed]
[6] Jiang, Y., Dai, A., Huang, Y., Li, H., Cui, J., Yang, H., et al. (2025) Ligand-induced Ubiquitination Unleashes LAG3 Immune Checkpoint Function by Hindering Membrane Sequestration of Signaling Motifs. Cell, 188, 2354-2371.e18. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, Z., Ren, C., Xiao, R., Ma, S., Liu, H., Dou, Y., et al. (2024) Palmitoylation of TIM-3 Promotes Immune Exhaustion and Restrains Antitumor Immunity. Science Immunology, 9, eadp7302. [Google Scholar] [CrossRef] [PubMed]
[8] Cotton, A.D., Nguyen, D.P., Gramespacher, J.A., Seiple, I.B. and Wells, J.A. (2021) Development of Antibody-Based Protacs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. Journal of the American Chemical Society, 143, 593-598. [Google Scholar] [CrossRef] [PubMed]
[9] Moon, Y., Cho, H., Kim, J., Song, S., Yeon Park, J., Young Min, J., et al. (2024) Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy. Angewandte Chemie International Edition, 64, e202414146. [Google Scholar] [CrossRef] [PubMed]
[10] Joller, N., Anderson, A.C. and Kuchroo, V.K. (2024) LAG-3, TIM-3, and TIGIT: Distinct Functions in Immune Regulation. Immunity, 57, 206-222. [Google Scholar] [CrossRef] [PubMed]
[11] Ren, X., Wang, L., Liu, L. and Liu, J. (2024) PTMs of PD-1/PD-L1 and Protacs Application for Improving Cancer Immunotherapy. Frontiers in Immunology, 15, Article 1392546. [Google Scholar] [CrossRef] [PubMed]
[12] 王静怡, 马晓林. E3泛素连接酶三结构域蛋白59对非小细胞肺癌细胞增殖和侵袭的影响[J]. 解剖学研究, 2024, 46(2): 139-144.
[13] 李玉, 应帅, 葛文, 等. HEK293T细胞中TRAF6多聚泛素化修饰KLF5的方式及其修饰位点的鉴定[J]. 南京医科大学学报(自然科学版), 2023, 43(4): 445-451.
[14] 杨思霞, 李深盼, 任晓虎, 等. 三氯乙烯致L-02细胞毒性中SET蛋白介导的组蛋白泛素化及类泛素化修饰鉴定[J]. 中国药理学与毒理学杂志, 2022, 36(7): 502-508.
[15] 黄彬, 张令强, 张学利. LUBAC介导RabGEF1的线性泛素化修饰[J]. 生物化学与生物物理进展, 2023, 50(4): 749-759.
[16] 杨丛语, 阿茹娜, 刘嘉铭. 膀胱癌铜死亡相关免疫检查点基因预后特征和免疫与药物治疗分析[J]. 海南医学院学报, 2024, 30(4): 262-272.
[17] Tang, X., Luo, Z., Xiong, Y., Yang, J., Shi, A., Zheng, K., et al. (2022) The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation. Cancers, 14, Article 5374. [Google Scholar] [CrossRef] [PubMed]
[18] Tang, X., Xiong, Y., Shi, X., Zhao, Y., Shi, A., Zheng, K., et al. (2022) IGSF11 and VISTA: A Pair of Promising Immune Checkpoints in Tumor Immunotherapy. Biomarker Research, 10, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[19] Ping, A.S., Yang, X.T., Lu, Y.X., et al. (2022) Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Frontiers in Immunology, 12, Article 785091.
[20] 陈佳玥, 王丰. 靶向免疫检查点B7-H3对肿瘤的免疫治疗作用[J/OL]. 中国生物化学与分子生物学报, 1-26.
https://kns.cnki.net/KCMS/detail/detail.aspx?DBName=cjfqtotal&dbcode=cjfq&filename=SWHZ202507002, 2025-06-30.
[21] Lara, B., Snyder, M., Fimbres, J., Yang, E., Song, G., Duggineni, V.K., et al. (2025) The AHR Regulates IFN-Induced Immune Checkpoints in Lung Cancer Cells through HNRNPH1, an RNA-Binding Protein, and INCR1, a Novel Long Non-Coding RNA. Journal of Biological Chemistry, 301, Article ID: 110316. [Google Scholar] [CrossRef] [PubMed]
[22] Nakamura, H., Konnai, S., Okagawa, T., Maekawa, N., Tiyamanee, W., Ikehata, M., et al. (2025) Comprehensive Analysis of Immune Checkpoint Molecules Profiles Phenotype and Function of Exhausted T Cells in Enzootic Bovine Leukosis. The Journal of Immunology, 214, 2600-2616. [Google Scholar] [CrossRef] [PubMed]
[23] Massalha, K.E., Buduo, D.A.C., Chédeville, L.A., et al. (2025) Defective Neutrophil Clearance in JAK2V617F Myeloproliferative Neoplasms Drives Myelofibrosis via Immune Checkpoint CD24. Blood, 146, 717-731.
[24] Spadotto, V., Ripamonti, C., Ghiroldi, A., Galbiati, E., Pozzi, P., Noberini, R., et al. (2025) Correction: HDAC6 Inhibition by ITF3756 Modulates PD-L1 Expression and Monocyte Phenotype: Insights for a Promising Immune Checkpoint Blockade Co-Treatment Therapy. Frontiers in Immunology, 16, Article 1645773. [Google Scholar] [CrossRef] [PubMed]
[25] 付强, 卢钟琦, 常颖, 等. 免疫检查点及抑制剂抗肿瘤作用的研究进展[J]. 实用医学杂志, 2025, 41(2): 288-293.
[26] 周迪, 韩楠男, 李华盛, 等. C3H/He鼠头颈鳞癌转移淋巴结内CD8+T细胞的关键基因、通路和免疫检查点表达分析[J]. 上海口腔医学, 2024, 33(6): 586-593.
[27] 刘志坤, 胡蓉, 郑舒丹, 等. 免疫检查点抑制剂在恶性黑色素瘤治疗中的应用及其疗效影响因素研究进展[J]. 山东医药, 2024, 64(33): 111-115.
[28] 杨燕, 陈丹, 朱红革. 非小细胞肺癌中免疫检查点及免疫治疗中细胞亚群的异质性[J]. 国际老年医学杂志, 2024, 45(6): 653-661.
[29] 徐向宁, 王引弟, 吕珍, 等. 基于PD-1/PD-L1免疫检查点通路中西医结合抗肿瘤治疗的研究进展[J]. 中国中医基础医学杂志, 2024, 30(7): 1258-1264.
[30] 李星原, 虞永峰, 穆书雅, 等. 免疫检查点抑制剂在表皮生长因子受体基因突变型晚期非小细胞癌中的应用现状与未来[J]. 肿瘤, 2024, 44(6): 555-565.
[31] 陈冬冬, 楼金金, 黄燕燕, 等. 基于免疫相关基因的肝细胞癌预后模型的构建和验证[J]. 解剖学报, 2024, 55(3): 319-328.
[32] 周立坤. TRIM5通过泛素化降解nsp12抑制猪繁殖与呼吸综合征病毒的复制[D]: [硕士学位论文]. 郑州: 河南农业大学, 2024.
[33] 张世龙. NAP1L1调控BIRC2泛素化降解促进肝细胞癌进展的机制研究[D]: [博士学位论文]. 贵阳: 贵州医科大学, 2024.
[34] 刘湘雅. 负载LSECtin抗体的磁性氧化铁纳米颗粒用于增强肝癌免疫检查点阻断治疗[D]: [硕士学位论文]. 衡阳: 南华大学, 2024.